The Competing Interests statement is incorrect. The correct Competing Interests statement is as follows: LXS (now known as Encala™) was a product of BioMolecular Products, Inc and was used for the clinical trial. Envara Health was founded in 2018 to develop therapeutic nutrition products related to the licensed LXS (now Encala™) technology. After study completion, VAS co-founded Envara Health and serves as a consultant.
Reference
- 1. Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020) Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(5): e0232685. https://doi.org/10.1371/journal.pone.0232685 pmid:32384122
Citation: Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020) Correction: Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(9): e0239642. https://doi.org/10.1371/journal.pone.0239642
Published: September 17, 2020
Copyright: © 2020 Stallings et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.